TrialBMC cancer2014

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.

Shibani Nicum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.